In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 16251-45-9, name is (4S,5R)-4-Methyl-5-phenyloxazolidin-2-one, introducing its new discovery. Recommanded Product: (4S,5R)-4-Methyl-5-phenyloxazolidin-2-one
SULFOXIMINE AND SULDODIIMINE MATRIX METALLOPROTEINASE INHIBITORS
Novel sulfoximine and sulfodiimine matrix metalloproteinase inhibitors of the formula, STR1 wherein: R 1 is selected from the group consisting of lower-alkyl, hydroxy lower-alkyl, amino lower-alkyl, carbamoyl lower-alkyl, lower-alkyl carbonyl, lower-alkyoxyalkyl, aralkyl and heteroaralkyl;
X is NH or O;
R 2 is selected from the group consisting of hydrogen, lower-alkyl and aralkyl;
R 3 is selected from the group consisting of hydrogen, lower-alkyl, amino lower-alkyl, guanyl lower-alkyl, aralkyl and heteroaralkyl; and
R 4 is selected from the group consisting of lower alkyl, aralkyl and–CH(R 5)–C(O)NH 2,
wherein R 5 is selected from the group consisting of hydrogen, lower-alkyl, amino lower-alkyl, guanyl lower-alkyl, imidazoylalkyl, hydroxymethyl, 1-hydroxyethyl, mercapto lower-alkyl, and methylthio lower-alkyl;
useful for modulating physiological functions or treating diseases and disease conditions associated with matrix metalloproteinase modulation.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 16251-45-9, and how the biochemistry of the body works.Recommanded Product: (4S,5R)-4-Methyl-5-phenyloxazolidin-2-one
Reference£º
Oxazolidine – Wikipedia,
Oxazolidine | C3H2128NO – PubChem